Clinical trial
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in…
NCT04640077 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT04640077 |
|---|---|
| Title | A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) |
| Official title | Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment |
| Intervention type | Drug, Other |
| Interventions | No Intervention, donanemab |
| Enrollment | 95 |
| Start date | Nov 23, 2020 |
| Primary completion | Feb 27, 2024 |
| Completion | Feb 27, 2024 |
| First posted | Nov 23, 2020 |
| Last update posted | Jun 13, 2025 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: